Research presented at the Association for Research in Vision and Ophthalmology annual meeting reveals a connection between mitochondrial disease and dementia risk.

Sylentis has released promising topline results from its Phase 2a study evaluating SYL1801, an eye drop therapy for the treatment of neovascular age-related macular

“Super vision” may be one step closer, with neuroscientists and materials scientists creating infrared contact lenses.

Carl Zeiss Vision International has announced an agreement to acquire Brighten Optix, enhancing its portfolio of myopia management and also integrating specialty contact lenses.